Jazz Pharmaceuticals touted the benefits of Solriamfetol via a new study at the recently concluded virtual edition of the CHEST Annual Meeting. An post conference wrap-up highlights a study of the compound treats excessive daytime sleepiness (EDS) due to obstructive sleep apnea (OSA).
The study titled “
LONG-TERM EFFECTS OF SOLRIAMFETOL ON EXCESSIVE DAYTIME SLEEPINESS AND FUNCTIONAL OUTCOMES IN PARTICIPANTS WITH OSA “presented at the CHEST Annual Meeting 2020 evaluated Solriamfetol’s efficacy on functional outcomes in a long-term study’s randomized withdrawal (RW) phase.
“The present analysis included patients with OSA who took part in a previous trial of solriamfetol,”. “Open-label solriamfetol treatment was performed for about six months, at which time a subgroup of patients was randomized for the two-week RW phase to receive either placebo (n=101) or solriamfetol (n=99).”
Assessments included change in Functional Outcomes of Sleep Questionnaire (FOSQ-10) total score and Epworth Sleepiness Scale (ESS) score from initiation to conclusion, as well as the percentage of patients who were reported as worse per the Patient Global Impression of Change (PGI-C) and Clinician Global Impression of Change (CGI-C). D’Onofrio explains that, “By the end of the RW phase, placebo patients experienced worsening FOSQ-10 total scores (least squares [LS] mean change, –2.4), while the solriamfetol group maintained their scores (LS mean change, –0.8; LS mean difference, 1.6; 95% confidence interval [CI], 0.80-2.37; P=0.0001).”
Researchers concluded: “These data support long-term maintenance of efficacy of solriamfetol for treating EDS and improving daily functioning in patients with OSA.”
Source: American College of Chest Physicians